세계의 크라베병 치료 시장

Global Krabbe Disease Treatment Market to Reach US$2.2 Billion by 2030

The global market for Krabbe Disease Treatment estimated at US$1.5 Billion in the year 2024, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Anticonvulsants, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$823.5 Million by the end of the analysis period. Growth in the Muscle Relaxants segment is estimated at 5.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$416.7 Million While China is Forecast to Grow at 5.9% CAGR

The Krabbe Disease Treatment market in the U.S. is estimated at US$416.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$340.6 Million by the year 2030 trailing a CAGR of 5.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.7% and 5.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Krabbe Disease Treatment Market - Insights & Medical Advancements

What Is Krabbe Disease and Why Is It a Significant Focus in Rare Disease Research?

Krabbe disease, also known as globoid cell leukodystrophy, is a rare and often fatal genetic disorder that affects the central nervous system. It is caused by mutations in the GALC gene, which lead to the accumulation of galactolipids in the brain, resulting in the destruction of the myelin sheath that insulates nerve cells. This progressive demyelination causes severe neurological impairment, including developmental delays, muscle weakness, and vision loss, often leading to death in early childhood. Due to its rarity and the severe nature of its symptoms, Krabbe disease is a significant focus in rare disease research. The condition poses considerable challenges for diagnosis and treatment, with current therapeutic options being limited primarily to symptomatic management and bone marrow transplantation in very early stages. However, ongoing research is exploring novel treatment approaches, including gene therapy and enzyme replacement therapy, to provide more effective and potentially curative options.

How Are Advancements in Gene Therapy and Early Diagnosis Impacting Krabbe Disease Treatment?

Advancements in gene therapy and early diagnosis are significantly impacting the landscape of Krabbe disease treatment, offering new hope for affected individuals and their families. Gene therapy, which involves delivering a functional copy of the defective GALC gene to the patient’s cells, is one of the most promising areas of research. Preclinical studies and early-phase clinical trials have shown that gene therapy has the potential to halt or even reverse the progression of Krabbe disease by restoring the enzyme activity needed to prevent toxic buildup in the brain. Additionally, improvements in newborn screening programs are enabling earlier diagnosis of Krabbe disease, which is crucial for the timely initiation of treatment. Early detection allows for interventions such as hematopoietic stem cell transplantation (HSCT), which has been shown to be more effective when performed before the onset of symptoms. These advancements are paving the way for more effective treatment strategies and improving the prognosis for patients with Krabbe disease.

What Challenges Does the Krabbe Disease Treatment Market Face?

The Krabbe disease treatment market faces several challenges, including the rarity of the condition, the complexity of treatment, and the high costs associated with research and therapy development. As a rare disease, Krabbe disease affects a small patient population, which can limit the financial incentives for pharmaceutical companies to invest in research and development. Additionally, the treatment of Krabbe disease, particularly in its advanced stages, is highly complex and often requires multidisciplinary care, including neurologists, geneticists, and palliative care specialists. The cost of treatments, such as gene therapy and stem cell transplantation, can be prohibitively high, raising concerns about accessibility and reimbursement. Furthermore, the development of effective therapies is challenged by the need for a deep understanding of the disease’s underlying mechanisms and the difficulties in delivering treatments across the blood-brain barrier. To address these challenges, there is a growing focus on collaboration between researchers, healthcare providers, patient advocacy groups, and pharmaceutical companies to drive innovation and ensure that emerging therapies reach those in need.

What Factors Are Driving Growth in the Krabbe Disease Treatment Market?

The growth in the Krabbe disease treatment market is driven by several factors, including advancements in genetic research, increased awareness and early diagnosis, and the development of novel therapies. The rapid progress in genetic research is leading to a better understanding of the molecular mechanisms underlying Krabbe disease, paving the way for the development of targeted therapies such as gene therapy and enzyme replacement therapy. The expansion of newborn screening programs and early diagnostic tools is also driving growth by enabling earlier intervention, which is critical for improving treatment outcomes. Additionally, the increasing focus on rare diseases within the pharmaceutical industry, supported by government incentives and orphan drug designations, is spurring investment in the development of new treatments for Krabbe disease. As these advancements continue, the market for Krabbe disease treatment is expected to grow, offering new hope for patients and their families.

SCOPE OF STUDY:

The report analyzes the Krabbe Disease Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy (Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT), Other Therapies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

• Abbott Laboratories
• CENETOGENE N.V.
• GlaxoSmithKline
• Johnson & Johnson
• Novartis AG
• Pfizer
• Sanofi-Aventis SA
• Shire
• Teva Pharmaceutical Industries Ltd.
• UCB Pharmaceuticals

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Krabbe Disease Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • Global Economic Update
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Awareness of Krabbe Disease Spurs Growth in the Treatment Market
  • Advancements in Gene Therapy Expand Addressable Market for Krabbe Disease Treatment
  • Rise in Newborn Screening Programs Propels Early Diagnosis and Treatment
  • Technological Innovations in Stem Cell Therapy Strengthen the Business Case for Krabbe Disease Treatments
  • Growing Focus on Rare Diseases and Orphan Drugs Throws the Spotlight on Krabbe Disease
  • Expansion of Specialized Treatment Centers Expands Access to Krabbe Disease Care
  • Increased Investment in R&D for Neurological Disorders Sustains Growth in Krabbe Disease Treatments
  • Growing Importance of Personalized Medicine Propels Innovation in Krabbe Disease Treatment
  • Shift Towards Multidisciplinary Care Models Strengthens the Treatment Ecosystem for Krabbe Disease
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Krabbe Disease Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Krabbe Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Krabbe Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Anticonvulsants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Muscle Relaxants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Muscle Relaxants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Muscle Relaxants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Hematopoietic Stem Cell Transplantation (HSCT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Hematopoietic Stem Cell Transplantation (HSCT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Hematopoietic Stem Cell Transplantation (HSCT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 17: USA Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 18: USA Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: USA 15-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 20: Canada Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 21: Canada Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: Canada 15-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2015, 2025 & 2030
• JAPAN
  • Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 23: Japan Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 24: Japan Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: Japan 15-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2015, 2025 & 2030
• CHINA
  • Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 26: China Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 27: China Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: China 15-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2015, 2025 & 2030
• EUROPE
  • Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 29: Europe Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: Europe Historic Review for Krabbe Disease Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: Europe 15-Year Perspective for Krabbe Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 32: Europe Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Europe Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: Europe 15-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2015, 2025 & 2030
• FRANCE
  • Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 35: France Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: France Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: France 15-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2015, 2025 & 2030
• GERMANY
  • Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 38: Germany Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Germany Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: Germany 15-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 41: Italy Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Italy Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: Italy 15-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 44: UK Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: UK Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: UK 15-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Rest of Europe Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Rest of Europe 15-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Asia-Pacific Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Asia-Pacific 15-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2015, 2025 & 2030
• REST OF WORLD
  • TABLE 53: Rest of World Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Rest of World Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Rest of World 15-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2015, 2025 & 2030

IV. COMPETITION